Press Release - Company Data

Oculus Innovative Sciences Reports Revenues of $15.5 Million for Fiscal Year 2013, Product Revenue Up 23 Percent
Posted 2013-06-13 06:26NAI Editing
today announced financial results for the fourth quarter of fiscal year 2013, ended March 31, 2013.

Oculus Innovative Sciences Announces Two Key Agreements With Company's Subsidiary, Ruthigen, Inc
Posted 2013-06-05 23:35NAI Editing
announced today that the company has entered into two key agreements, which establish the license and supply as well as shared services with its wholly owned subsidiary, Ruthigen, Inc., which is focus

Oculus Announces Confidential Submission of Draft Registration Statement for Initial Public Offering to Securities and Exchange Commission by Its Subsidiary Ruthigen, Inc.
Posted 2013-05-27 23:42NAI Editing
a global healthcare company that designs, manufactures and markets prescription and non-prescription products in over 20 countries, today announced that Ruthigen, Inc., a wholly owned subsidiary of th

Oculus Innovative Sciences Announces New Regulatory Approvals for Microcyn(R)-Based Antiseptic Products in Panama and El Salvador
Posted 2013-05-01 00:32NAI Editing
a global healthcare company that designs, manufactures and markets prescription and non-prescription products in over 20 countries, today announced new regulatory approvals for Microcyn®-based antisep

Oculus Innovative Sciences Announces New Regulatory Approvals and Target Launch Dates for Three New Microcyn(R)-Based Products in Middle East Countries
Posted 2013-04-24 00:39NAI Editing
a global healthcare company that designs, manufactures and markets prescription and non-prescription products in over 20 countries, today announced new regulatory approvals in Dubai, United Arab Emira

Oculus Innovative Sciences to Rollout Five New Microcyn(R) Technology-Based Products in Singapore and Malaysia
Posted 2013-04-10 00:41NAI Editing
a global healthcare company that designs, manufactures and markets prescription and non-prescription products in over 20 countries, today announced that the company's partner in that region, Dyamed Bi

Oculus Innovative Sciences Strengthens Intellectual Property Portfolio With Issuance of Three New International Patents for Microcyn(R) Technology
Posted 2013-04-04 00:38NAI Editing
a global healthcare company that designs, manufactures and markets prescription and non-prescription products in over 20 countries, today announced the issuance of three new international patents for

Oculus Innovative Sciences Expands Regulatory Claims for Microcyn-Based Advanced Wound Management Products in Europe
Posted 2013-03-26 00:45NAI Editing
a healthcare company a global healthcare company that designs, manufactures and markets prescription and non-prescription products in over 20 countries, today announced that is has been granted a recl

Oculus Innovative Sciences Appoints Jerry McLaughlin to Its Board of Directors
Posted 2013-03-20 02:22NAI Editing
announced today the appointment of John G. (Jerry) McLaughlin to its board of directors.

Oculus Innovative Sciences Announces Completion of Patient Follow-Up in Scar Management Study
Posted 2013-03-14 00:41NAI Editing
a commercial healthcare company that designs, produces and markets innovative, safe and effective drugs, devices and nutritional products, including Microcyn® Technology solutions which are used in mu